Furci Fabiana, Scaramozzino Marco Umberto, Talesa Giuseppe Rocco, Pelaia Corrado
Provincial Healthcare Unit, Section of Allergology, 89900 Vibo Valentia, Italy.
"La Madonnina" Outpatient Clinic, 89100 Reggio Calabria, Italy.
Biomedicines. 2025 Jan 15;13(1):197. doi: 10.3390/biomedicines13010197.
Asthma is a chronic inflammatory disease with the main anti-inflammatory drugs for better disease control being steroids or corticosteroids. The use of steroids in asthma patients, in particular in uncontrolled asthma patients, is associated with an increased risk of osteoporosis and fragility fractures. A single oral corticosteroid course increases the risk of osteoporosis and the continual use of inhaled corticosteroids is correlated over time to an increased risk for both bone conditions. With the use of new, available biologic therapies for asthma, perhaps even anticipating the times of their use in therapeutic management, in the current guidelines and with targeted strategies of prevention it may be possible to improve asthma management, preventing some comorbidities, such as osteoporosis.
哮喘是一种慢性炎症性疾病，用于更好地控制疾病的主要抗炎药物是类固醇或糖皮质激素。在哮喘患者中使用类固醇，尤其是在未得到控制的哮喘患者中，会增加骨质疏松和脆性骨折的风险。单次口服糖皮质激素疗程会增加骨质疏松的风险，随着时间的推移，持续使用吸入性糖皮质激素与这两种骨骼疾病风险的增加相关。随着新型可用的哮喘生物疗法的应用，甚至在预期其用于治疗管理之前，在当前指南以及有针对性的预防策略中，或许有可能改善哮喘管理，预防一些合并症，如骨质疏松。
